Term ends Jun 3, 2031 · Medium confidence
20-year base term ends Jun 3, 2031
Why Medium: The disclaimer's references carry disclaimers of their own not yet read (US 8,999,999), so the cap could be lower.
Held by Pharmacyclics LLC
Filed Nov 26, 2013 as application 14/091,196 · Granted Oct 31, 2017
Base term, 20 years from filing
Today
2011
2031
Clock starts
Jun 3, 2011
Jun 3, 2011
Term ends
Jun 3, 2031
Jun 3, 2031
Granted
Oct 31, 2017
Oct 31, 2017
base term
fee events
Updated Nov 14, 2026 · includes USPTO assignment & status data published Nov 14, 2026 and grant & fee data published Nov 10, 2026 (weekly) · how we know
None
Term adjustment
No prosecution delay on this record.
No effect
Terminal disclaimer
Resolved from the filed document, referencing US 8,999,999, to Jun 3, 2031. The term already ends on or before that date, so the cap shortened nothing.
2 of 3
Maintenance fees paid
Three maintenance fees fall due, at 3.5, 7.5 and 11.5 years from grant. This counts the ones the record shows paid.
25
Family applications on record here
Applications sharing this one's continuity chain whose file history this site holds. The family may have others.
This patent's term is its 20-year base term, with no adjustment for prosecution delay. A terminal disclaimer is resolved from the filed document, and it ends no earlier than this term, so it shortens nothing. 2 of 3 maintenance fees are paid so far. Confidence: Medium. from the record
How we calculated this date
One row per rule, each showing its own input and what it did to the date. A step we could not verify says so instead of resolving itself.
| Step | Input | Date after this step | Confidence |
|---|---|---|---|
| Base term, 20 years from filing | Clock starts Jun 3, 2011, when application 13/153,317, the earliest non-provisional in its chain, was filed (this one was filed Nov 26, 2013) | Jun 3, 2031 | High confidence |
| Continuity chain | Every parent in the chain resolved | no change | High confidence |
| Patent term adjustment | None on file | no change | High confidence |
| Terminal disclaimer cap | Disclaimer resolved from the filed document (refs US 8,999,999) | resolves to Jun 3, 2031, no earlier than this term, so no change | Medium confidence |
| Patent term extension | None on file | no change | High confidence |
| Fee events | 2 of 3 maintenance fees paid | In force | High confidence |
| Computed term end | The steps above, in order | Jun 3, 2031 | Medium confidence |
This family
| Application 13/153,317 | Abandoned not computed | not computed |
| US 8,754,090 | In force no later than Jun 2031 | no later than Jun 2031 |
| Application 13/340,533 | Abandoned not computed | not computed |
| Application 13/736,812 | Abandoned not computed | not computed |
| US 8,999,999 | In force no later than Jun 2031 | no later than Jun 2031 |
| Application 13/747,319 | Abandoned not computed | not computed |
| Application 13/869,700 | Abandoned not computed | not computed |
| US 9,801,881 | this patent Jun 2031 | Jun 2031 |
8 of 25 applications in this family shown, earliest filings first. The applications whose file history this site holds. The family may have others.
Assignments
Assignment documents as recorded at the USPTO, oldest first, with the reel and frame each was recorded at. A recorded assignment is a filed document, not a statement of current ownership, and the absence of a later one is not evidence that the last one still stands.
| Recorded | Assignor | Assignee | Conveyance |
|---|---|---|---|
| Jul 16, 2014 Reel 33328, frame 614 | Buggy, Joseph J.; Elias, Laurence; Fyfe, Gwen; Hedrick, Eric; Loury, David J.; Mody, Tarak D. | Pharmacyclics, Inc. | Assignment of Assignor's Interest |
| Jul 10, 2015 Reel 36058, frame 429 | Oxford Amherst Corporation | Pharmacyclics, Inc. | Merger |
| Jul 10, 2015 Reel 36058, frame 755 | Pharmacyclics, Inc.; Oxford Amherst LLC | Pharmacyclics LLC | Merger and Change of Name |
| May 17, 2016 Reel 38722, frame 1 | Oxford Amherst Corporation; Parmacyclics, Inc. | Pharmacyclics, Inc. | Corrective Assignment to Correct the Conveying Party Data Previously Recorded on Reel 036058 Frame 0429. Assignor(S) Hereby Confirms the Merger. |
| May 17, 2016 Reel 38722, frame 43 | Pharmacyclics, Inc.; Oxford Amherst LLC | Pharmacyclics LLC | Corrective Assignment to Correct the Conveying Party Data Previously Recorded on Reel 036058 Frame 0755. Assignor(S) Hereby Confirms the Merger and Change of Name. |
Sources
Google Patents · The patent document at USPTO · Assignment records at USPTO
USPTO account required: This application in Patent Center · USPTO's maintenance fee lookup
Maintenance fee events come from USPTO's own fee records. Its fee lookup asks for the patent number and the application number.
Free plan: 3 watched companies. Pro: unlimited.
Alerts on its grants, lapses and transfers.
What's changing
Jun 2031
Term ends Jun 3, 2031. Maintenance fees still fall due before then
Terminal disclaimer
A terminal disclaimer resolved from the filed document, referencing US 8,999,999, ends no earlier than this term, so it caps nothing.
Citations
73
later US patents cite this one
That is top 5% of utility patents granted in 2017 in our data, the only group it is compared against.
How we rank
Every date shows its work: the base term, any term adjustment or extension, any disclaimer cap, and the maintenance fee record, each with a confidence tier. How this record was built
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.
In force means the term is running and no lapse is on record. It is not a finding that the patent is valid.